Celldex Therapeutics (CLDX) is a clinical-stage biotechnology company that focuses on developing targeted therapies for rare ...

Chronic spontaneous urticaria (CSU) is responsible for 80% of all cases of chronic hives, but 90% of people never know what ...

The Chronic Urticaria Or Hives drugs in development market research report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with ...

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Celldex Therapeutics reported Wednesday that its experimental medicine for a condition that causes chronic hives reduced hive activity in patients, completely clearing it in some. However ...

Leerink Partners analyst Thomas Smith maintained a Buy rating on Celldex (CLDX – Research Report) on October 14 and set a price target of ...

In spite of treatment advances, chronic urticaria continues to impair patients' health-related quality of life (HRQoL) and drive up direct and indirect healthcare costs. As early as 1997 ...

They can be big or small, vary in shape, and can appear anywhere on the body. Hives typically pop up as a result of an allergic reaction to food items or medicines. They can be acute, and last less ...

In many cases, an over-the-counter antihistamine or corticosteroid will suffice. Urticaria, or hives, is a common skin rash. Hives can be acute (short-term) if present for less than six weeks. Chronic ...